• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Calcipressin-2 (RCAN2)

ACP18147

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP18147 Target NameRCAN2
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range1-197Protein LengthFull length protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ14206
Background Information
  • Uniprot Id

    Q14206

  • Target Species

    Human

  • Target Name

    RCAN2

  • Target Full Name

    Calcipressin-2

  • Target Function

    Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development.

  • Target Protein Families

    RCAN family

  • Target Tissue Specificity

    Expressed in fibroblasts, heart, brain, liver, and skeletal muscle but not in placenta, lung, kidney and pancreas.

  • Target Synonyms

    Calcipressin 2; Calcipressin-2; CSP2; Down syndrome candidate region 1-like 1; Down syndrome critical region gene 1 like 1 protein; DSCR1L1; MCIP2; Myocyte enriched calcineurin interacting protein 2; Myocyte-enriched calcineurin-interacting protein 2; RCAN2; RCAN2_HUMAN; RCN2; Regulator of calcineurin 2; Thyroid hormone responsive gene ZAKI4; Thyroid hormone responsive protein ZAKI4; thyroid hormone-responsive (skin fibroblasts); Thyroid hormone-responsive protein ZAKI-4; ZAKI4

Inquire Recombinant Human Calcipressin-2 (RCAN2) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification